These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Rizatriptan wafer--sublingual vs. placebo at the onset of acute migraine. Allen C; Dayno J; Lines C; McCarroll K Cephalalgia; 2001 Feb; 21(1):77. PubMed ID: 11298669 [No Abstract] [Full Text] [Related]
25. Increasing the effect of triptans in migraine. Tfelt-Hansen P; Olesen J Lancet; 2006 Oct; 368(9544):1313-4. PubMed ID: 17046449 [No Abstract] [Full Text] [Related]
26. Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Diener HC; Dowson AJ; Ferrari M; Nappi G; Tfelt-Hansen P Cephalalgia; 1999 Oct; 19(8):699-700. PubMed ID: 10570722 [No Abstract] [Full Text] [Related]
27. Rizatriptan in acute treatment of migraine: update on new comparative data. Goadsby PJ Cephalalgia; 2000; 20 Suppl 1():10-5. PubMed ID: 11078004 [No Abstract] [Full Text] [Related]
28. Oral migraine drug approved for marketing. Am J Health Syst Pharm; 1998 Aug; 55(16):1656. PubMed ID: 9740896 [No Abstract] [Full Text] [Related]
29. Therapeutic gain: a critique. Spierings EL Headache; 1999; 39(7):517-8. PubMed ID: 11279939 [No Abstract] [Full Text] [Related]
30. The truth about frovatriptan. Tfelt-Hansen P; Steiner T Headache; 2003 Jun; 43(6):699-700; author reply 697-9. PubMed ID: 12786937 [No Abstract] [Full Text] [Related]
32. Sum of Pain Intensity Differences (SPID) in migraine trials. A comment based on four rizatriptan trials. Tfelt-Hansen P; McCarroll K; Lines C Cephalalgia; 2002 Oct; 22(8):664-6. PubMed ID: 12383062 [TBL] [Abstract][Full Text] [Related]
33. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew. Goldstein D Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072 [No Abstract] [Full Text] [Related]